Skip to main content
Premium Trial:

Request an Annual Quote

Proteome Sciences Wins Over $1M From EU, UK Government

NEW YORK, Feb. 13 (GenomeWeb News) - Proteome Sciences has won

438,000 ($563,000) from the European Union, and £419,000 ($794,000) from the UK government, to conduct research into anti-depressant drugs and into Alzheimer's disease, respectively, the company said today.

 

The EU award is part of a 7.5 million, three-year multi-center pharmacogenomics grant from the EU's 6th Framework Program. Proteome Sciences will explore patients' response to anti-depressants, with the aim to predict responders, find early disease indicators, and discover new drug targets.

 

The UK government grant, jointly awarded to Cobham, UK-based Proteome Sciences and the Institute of Psychiatry at Kings College, London, will fund the discovery of new biomarkers and targets for Alzheimer's.

 

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.